Old Web
English
Sign In
Acemap
>
authorDetail
>
Jennifer Bourque
Jennifer Bourque
Merck & Co.
non-small cell lung cancer (NSCLC)
Dosing
Pembrolizumab
Medicine
Pathology
2
Papers
79
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
2015
Journal of Clinical Oncology
Vassiliki Papadimitrakopoulou
Amita Patnaik
Hossein Borghaei
James P. Stevenson
Leena Gandhi
Matthew A. Gubens
James Chih-Hsin Yang
Lecia V. Sequist
Joy Yang Ge
Jennifer Bourque
Robert Bachman
Ellie Im
Shirish M. Gadgeel
Show All
Source
Cite
Save
Citations (28)
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
2015
Journal of Clinical Oncology
Amita Patnaik
Mark A. Socinski
Matthew A. Gubens
Leena Gandhi
James P. Stevenson
Robert Bachman
Jennifer Bourque
Joy Yang Ge
Ellie Im
Shirish M. Gadgeel
Show All
Source
Cite
Save
Citations (51)
1